KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation & Amortization (CF) (2017 - 2025)

Aquestive Therapeutics has reported Depreciation & Amortization (CF) over the past 9 years, most recently at $130000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $130000.0 for Q4 2025, down 11.56% from a year ago — trailing twelve months through Dec 2025 was $548000.0 (down 23.68% YoY), and the annual figure for FY2025 was $548000.0, down 23.68%.
  • Depreciation & Amortization (CF) for Q4 2025 was $130000.0 at Aquestive Therapeutics, down from $139000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for AQST hit a ceiling of $755000.0 in Q1 2021 and a floor of $130000.0 in Q4 2025.
  • Median Depreciation & Amortization (CF) over the past 5 years was $307000.0 (2023), compared with a mean of $398100.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): increased 17.63% in 2023 and later crashed 68.52% in 2024.
  • Aquestive Therapeutics' Depreciation & Amortization (CF) stood at $731000.0 in 2021, then plummeted by 45.69% to $397000.0 in 2022, then increased by 17.63% to $467000.0 in 2023, then crashed by 68.52% to $147000.0 in 2024, then dropped by 11.56% to $130000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $130000.0 (Q4 2025), $139000.0 (Q3 2025), and $140000.0 (Q2 2025) per Business Quant data.